ASSESSMENT OF THE EFFICACY AND SAFETY OF ANIDULAFUNGIN, COMPARED WITH OTHER AVAILABLE ANTIFUNGALTHERAPIES TO TREAT INVASIVE CANDIDIASIS- A NETWORK META-ANALYSIS
Author(s)
Reyes J1, Castaño Gamboa N1, Rodriguez A2
1Pfizer SAS, Bogotá, Colombia, 2Universidad Nacional de Colombia, Bogota, Colombia
OBJECTIVES: Determine the efficacy and safety of the anidulafungin compared to other available antifungal therapies to treat invasive candidiasis (IC) in adults METHODS: We undertook a systematic review. MEDLINE, COCHRANE, EMBASE, LILACS and clinicaltrials.gov databases were used to find randomised controlled trials (RCTs). Two independent researchers selected the RCTs, implemented the data management, and assessed the risk of bias with Cochrane criteria. Key outcomes such as global response, all-cause mortality, hepatoxicity, and nephrotoxicity were assessed through Bayesian analysis. The three assumptions of network meta-analysis were evaluated following the recommendations in the technical document of NICE. We estimated the best treatment probability in order to establish the rank of treatments in each outcome. Additionally, the quality of evidence was assessed using the GRADE methodology. Results were expressed as difference of risk (DR). RESULTS: We included 10 RCTs which met the eligibility criteria. According to the analysis of best treatment, anidulafungin had the highest probability (0.46) of global response, followed by micafungin (0.41), and also demonstrated statistical difference with fluconazole (DR -0.18, 95%CrI -0.29-(-0.08)). Anidulafungin had less all-cause mortality compared with amphotericin B deoxycolate (AmpB)(DR 0.12, 95%CrI 0.03-0.24), micafungin (DR 0.20, 95%CrI 0.03-0.37) and caspofungin (DR 0.17, 95%CrI 0.04-0.34). Related to safety events, anidulafungin had less hepatotoxicity than fluconazole (DR 0.08, 95%CrI 0.01-0.23). No significant differences in nephrotoxicity between the treatments was found due to heterogeneity, however, there was a possible clinical difference between anidulafungin and AmpB (DR 0.26, 95%CrI -0.03-0.92). The quality of the evidence was moderate to low in the majority of the outcomes mainly due to risk of bias and imprecision. CONCLUSIONS: The network meta-analysis suggests that anidulafungin may be an effective and safe treatment for IC when it is compared with other available antifungals.
Conference/Value in Health Info
2018-11, ISPOR Europe 2018, Barcelona, Spain
Value in Health, Vol. 21, S3 (October 2018)
Code
PIN113
Topic
Health Technology Assessment
Topic Subcategory
Decision & Deliberative Processes
Disease
Infectious Disease (non-vaccine)